T Cell Antigen Receptor Vaccines for Active Therapy of T Cell Malignancies

T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72794/1/j.1749-6632.2001.tb03714.x.pd